88912-22-5

Usage

Uses

Used in Pharmaceutical Industry:
5-CHLORO-2-METHOXY-ISONICOTINIC ACID is used as an active pharmaceutical ingredient for its ability to inhibit the growth of certain fungi and bacteria, contributing to the development of new medications targeting these microorganisms.
Used in Antifungal Applications:
In the field of antifungal medicine, 5-CHLORO-2-METHOXY-ISONICOTINIC ACID is used as an antifungal agent to combat fungal infections by inhibiting the growth of specific fungi, thereby providing a treatment option for various fungal-related conditions.
Used in Antibacterial Applications:
Similarly, in antibacterial medicine, 5-CHLORO-2-METHOXY-ISONICOTINIC ACID is utilized as an antibacterial agent to suppress the growth of certain bacteria, offering a potential solution for bacterial infections and contributing to the development of new antibiotics.
Used in Anti-inflammatory Applications:
5-CHLORO-2-METHOXY-ISONICOTINIC ACID is also studied for its potential as an anti-inflammatory agent, which could be used to reduce inflammation and alleviate symptoms associated with inflammatory conditions.
Used in Antioxidant Applications:
Furthermore, its antioxidant properties suggest that 5-CHLORO-2-METHOXY-ISONICOTINIC ACID could be employed in applications aimed at neutralizing free radicals and preventing oxidative stress, thus contributing to overall health and wellness.

InChI:InChI=1/C7H6ClNO3/c1-12-6-2-4(7(10)11)5(8)3-9-6/h2-3H,1H3,(H,10,11)

Upstream product

• 124-41-4 sodium methylate 
• 88912-26-9 2,5-dichloro-4-pyridinecarboxylic acid 

Relevant academic research and scientific papers

Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X7 Receptor Antagonist

Adamantanyl benzamide 1 was identified as a potent P2X7R antagonist but failed to progress further due to poor metabolic stability. We describe the synthesis and SAR of a series of bioisosteres of benzamide 1 to explore improvements in the pharmacological properties of this lead. Initial efforts investigated a series of heteroaromatic bioisosteres, which demonstrated improved physicochemical properties but reduced P2X7R antagonism. Installation of bioisosteric fluorine on the adamantane bridgeheads was well tolerated and led to a series of bioisosteres with improved physicochemical properties and metabolic stability. Trifluorinated benzamide 34 demonstrated optimal physicochemical parameters, superior metabolic stability (ten times longer than lead benzamide 1), and an improved physicokinetic profile and proved effective in the presence of several known P2X7R polymorphisms.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula II.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I), as follows: wherein R1, R2, R4, W, X, Y, and G, are defined herein.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III); wherein R1c, R2C, R4C, Wc, Yc, Zc and Gc, are defined herein.